Posts

Posted on

Super Micro Computer Inc. Announces Receipt of Extension from Nasdaq Stock Market

Super Micro Computer Inc. Announces Receipt of Extension from Nasdaq Stock Market

SAN JOSE, Calif.–(BUSINESS WIRE)–
Super Micro Computer, Inc. (NASDAQ:SMCI) (“SMCI” or the “Company”), a Total IT Solution Provider for AI, Cloud, Storage and 5G/Edge, today announced that on December 6, 2024, it received a letter from the Nasdaq Stock Market (“Nasdaq”) informing the Company that Nasdaq has granted the Company’s request for an exception to Nasdaq’s Listing Rule 5250(c)(1) through February 25, 2025. The exception gives the Company until February 25, 2025 to file its Annual Report on Form 10-K for the fiscal year ended June 30, 2024, its Quarterly Report on Form 10-Q for the period ended September 30, 2024 and any other required filings. The Company’s common stock will remain listed on the Nasdaq Global Select Market during the exception period. If the Company files all the required reports by February 25, 2025, the common stock will remain listed, so long as the Company remains in compliance with Nasdaq’s listing rules.

The Company currently expects to file all the required reports by February 25, 2025.

Cautionary Statement Regarding Forward Looking Statements

Statements contained in this press release that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements may relate, among other things, to the Company’s expectation that it will file all required reports by February 25, 2025. Such forward-looking statements do not constitute guarantees of future performance and are subject to a variety of risks and uncertainties that could cause our actual results to differ materially from those anticipated. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in our filings with the Securities and Exchange Commission, including those factors discussed under the caption “Risk Factors” in such filings.

About Super Micro Computer, Inc.

Supermicro (NASDAQ: SMCI) is a global leader in Application-Optimized Total IT Solutions. Founded and operating in San Jose, California, Supermicro is committed to delivering first to market innovation for Enterprise, Cloud, AI, and 5G Telco/Edge IT Infrastructure. We are a Total IT Solutions Provider with server, AI, storage, IoT, switch systems, software, and support services. Supermicro’s motherboard, power, and chassis design expertise further enable our development and production, enabling next generation innovation from cloud to edge for our global customers. Our products are designed and manufactured in-house (in the US, Taiwan, and the Netherlands), leveraging global operations for scale and efficiency and optimized to improve TCO and reduce environmental impact (Green Computing). The award-winning portfolio of Server Building Block Solutions® allows customers to optimize for their exact workload and application by selecting from a broad family of systems built from our flexible and reusable building blocks that support a comprehensive set of form factors, processors, memory, GPUs, storage, networking, power, and cooling solutions (air-conditioned, free air cooling or liquid cooling).

Supermicro, Server Building Block Solutions, and We Keep IT Green are trademarks and/or registered trademarks of Super Micro Computer, Inc.

Investor Relations Contact:

Nicole Noutsios

email: [email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Apps/Applications Technology 5G Telecommunications Software Internet Hardware Data Management Artificial Intelligence

MEDIA:

National Funds

Ticker

Distribution

Change From Prior Distribution

BlackRock Municipal Income Quality Trust*

BYM

$0.055500

–

BlackRock Long-Term Municipal Advantage Trust*

BTA

$0.049500

–

BlackRock MuniAssets Fund, Inc.*

MUA

$0.055500

–

BlackRock Municipal Income Fund, Inc.*

MUI

$0.055000

–

BlackRock Municipal Income Trust*

BFK

$0.050000

–

BlackRock Investment Quality Municipal Trust, Inc.*

BKN

$0.057000

–

BlackRock Municipal Income Trust II*

BLE

$0.054000

–

BlackRock Municipal 2030 Target Term Trust

BTT

$0.046400

–

BlackRock MuniHoldings Fund*

MHD

$0.059500

–

BlackRock MuniYield Quality Fund II, Inc.*

MQT

$0.051000

–

BlackRock MuniYield Quality Fund, Inc.*

MQY

$0.058000

–

BlackRock MuniHoldings Quality Fund II, Inc.*

MUE

$0.051000

–

BlackRock MuniVest Fund II, Inc.*

MVT

$0.054000

–

BlackRock MuniYield Fund, Inc.*

MYD

$0.054500

–

BlackRock MuniYield Quality Fund III, Inc.*

MYI

$0.055500

–

BlackRock MuniVest Fund, Inc.*

MVF

$0.036000

–

BlackRock 2037 Municipal Target Term Trust

BMN

$0.093750

–

State-Specific Funds

 

 Ticker

 

Distribution

Change From Prior Distribution

BlackRock MuniHoldings California Quality Fund, Inc.*

MUC

$0.053500

–

BlackRock California Municipal Income Trust*

BFZ

$0.059000

–

BlackRock MuniYield Michigan Quality Fund, Inc.*

MIY

$0.054500

–

BlackRock MuniHoldings New Jersey Quality Fund, Inc.*

MUJ

$0.054000

–

BlackRock MuniHoldings New York Quality Fund, Inc.*

MHN

$0.051500

–

BlackRock MuniYield New York Quality Fund, Inc.*

MYN

$0.051200

–

BlackRock New York Municipal Income Trust*

BNY

$0.051000

–

BlackRock MuniYield Pennsylvania Quality Fund*

MPA

$0.066000

–

BlackRock Virginia Municipal Bond Trust*

BHV

$0.051500

–

Taxable Municipal Fund:

Declaration- 12/6/2024   Ex-Date- 12/16/2024   Record- 12/16/2024   Payable- 12/23/2024

Fund

Ticker

Distribution

Change From Prior Distribution

BlackRock Taxable Municipal Bond Trust*

BBN

$0.092900

–

Taxable Fixed Income Funds:

Declaration- 12/6/2024   Ex-Date- 12/16/2024   Record- 12/16/2024   Payable- 12/23/2024

Fund

Ticker

Distribution

Change From Prior Distribution

BlackRock Floating Rate Income Trust*

BGT

$0.120280

–

BlackRock Core Bond Trust*

BHK

$0.074600

–

BlackRock Multi-Sector Income Trust*

BIT

$0.123700

–

BlackRock Income Trust, Inc.*

BKT

$0.088200

–

BlackRock Limited Duration Income Trust*

BLW

$0.113200

–

BlackRock Credit Allocation Income Trust*

BTZ

$0.083900

–

BlackRock Debt Strategies Fund, Inc.*

DSU

$0.098730

–

BlackRock Enhanced Government Fund, Inc.*

EGF

$0.041000

–

BlackRock Floating Rate Income Strategies Fund, Inc.*

FRA

$0.123840

–

BlackRock Corporate High Yield Fund, Inc.*

HYT

$0.077900

–

Equity Funds:

Declaration- 12/6/2024   Ex-Date- 12/16/2024   Record- 12/16/2024   Payable- 12/23/2024

Fund

Ticker

Distribution

Change From Prior

Distribution

BlackRock Health Sciences Term Trust*

BMEZ

$0.178090

0.001190

BlackRock Science and Technology Term Trust*

BSTZ

$0.218000

0.002510

BlackRock Innovation and Growth Term Trust*

BIGZ

$0.086760

0.000430

Multi-Asset Funds:

Declaration- 12/6/2024 Ex-Date- 12/16/2024 Record- 12/16/2024 Payable- 12/23/2024

Fund

Ticker

Distribution

Change From Prior

Distribution

BlackRock Capital Allocation Term Trust*

BCAT

$0.289190

0.000650

BlackRock ESG Capital Allocation Term Trust*

ECAT

$0.306840

0.001810

* In order to comply with the requirements of Section 19 of the Investment Company Act of 1940, as amended (the “1940 Act”), each of the Funds noted above posted to the DTC bulletin board and sent to its shareholders of record as of the applicable record date a Section 19 notice with the previous distribution payment. The Section 19 notice was provided for informational purposes only and not for tax reporting purposes. This information can be found in the “Closed-End Funds” section of www.blackrock.com. As applicable, the final determination of the source and tax characteristics of all distributions in 2024 will be made after the end of the year.

BlackRock Capital Allocation Term Trust (NYSE: BCAT), BlackRock ESG Capital Allocation Term Trust (NYSE: ECAT), BlackRock Science and Technology Term Trust (NYSE: BSTZ), BlackRock Health Sciences Term Trust (NYSE: BMEZ) and BlackRock Innovation and Growth Term Trust (NYSE: BIGZ) have adopted a managed distribution plan (a “Plan”) to support a level monthly distribution of income, capital gains and/or return of capital, or in the case of BMEZ, BSTZ, BIGZ, ECAT and BCAT a monthly distribution based on an annual rate of 12% (for BMEZ, BSTZ and BIGZ) and 20% (for ECAT and BCAT) of the Fund’s 12-month rolling average daily net asset value calculated 5 business days prior to declaration date of each distribution. The December 2024 distribution for each of BMEZ, BSTZ, BIGZ, ECAT and BCAT was calculated based on the average net asset value from 11/28/2023 to 11/27/2024. Below are the 12-month rolling average daily net asset values used to calculate BMEZ, BSTZ, BIGZ, ECAT and BCAT’s December distributions:

BMEZ: $17.808095

BSTZ: $21.799921

BIGZ: $8.675040

ECAT: $18.410000

BCAT: $17.351032

The fixed amounts distributed per share or distribution rate, as applicable, are subject to change at the discretion of each Fund’s Board of Directors/Trustees. Under its Plan, each Fund will distribute all available investment income to its shareholders, consistent with its investment objectives and as required by the Internal Revenue Code of 1986, as amended (the “Code”). If sufficient income (inclusive of net investment income and short-term capital gains) is not available on a monthly basis, a Fund will distribute long-term capital gains and/or return capital to its shareholders in order to maintain a level distribution.

Each Fund’s estimated sources of the distributions paid as of November 29, 2024 and for its current fiscal year are as follows:

Estimated Allocations as of November 29, 2024

Fund

Distribution

Net Income

Net Realized Short-Term Gains

Net Realized Long-Term Gains

Return of Capital

BMEZ1

$0.176900

$0 (0%)

$0 (0%)

$0 (0%)

$0.176900 (100%)

BSTZ1

$0.215490

$0 (0%)

$0 (0%)

$0 (0%)

$0.215490 (100%)

BIGZ1

$0.086330

$0 (0%)

$0 (0%)

$0 (0%)

$0.086330 (100%)

BCAT1

$0.288540

$0.032627 (11%)

$0 (0%)

$0 (0%)

$0.255913 (89%)

ECAT1

$0.305030

$0.015937 (5%)

$0 (0%)

$0 (0%)

$0.289093 (95%)

Estimated Allocations for the Fiscal Year through November 29, 2024

Fund

Distribution

Net Income

Net Realized Short-Term Gains

Net Realized Long-Term Gains

Return of Capital

BMEZ1

$1.512960

$0.040694 (3%)

$0 (0%)

$0 (0%)

$1.472266 (97%)

BSTZ1

$1.801010

$0 (0%)

$0 (0%)

$0.619326 (34%)

$1.181684 (66%)

BIGZ1

$0.747140

$0 (0%)

$0 (0%)

$0 (0%)

$0.747140 (100%)

BCAT1

$2.359050

$0.244754 (10%)

$0 (0%)

$0 (0%)

$2.114296 (90%)

ECAT1

$2.554050

$0.163438 (6%)

$0 (0%)

$0 (0%)

$2.390612 (94%)

1The Fund estimates that it has distributed more than its income and net-realized capital gains in the current fiscal year; therefore, a portion of your distribution may be a return of capital. A return of capital may occur, for example, when some or all of the shareholder’s investment is paid back to the shareholder. A return of capital distribution does not necessarily reflect the Fund’s investment performance and should not be confused with ‘yield’ or ‘income’. When distributions exceed total return performance, the difference will reduce the Fund’s net asset value per share.

The amounts and sources of distributions reported are only estimates and are being provided to you pursuant to regulatory requirements and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon each Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.

Fund Performance and Distribution Rate Information:

Fund

Average annual total return (in relation to NAV) for the 5-year period ending on 10/31/2024

Annualized current distribution rate expressed as a percentage of NAV as of 10/31/2024

Cumulative total return (in relation to NAV) for the fiscal year through 10/31/2024

Cumulative fiscal year distributions as a percentage of NAV as of 10/31/2024

BMEZ*

5.15%

12.30%

4.83%

7.74%

BSTZ

11.57%

11.80%

11.18%

7.24%

BIGZ*

(14.24%)

12.60%

(0.66%)

8.04%

BCAT*

4.90%

20.66%

10.23%

12.35%

ECAT*

6.70%

20.43%

12.89%

12.55%

* Portfolio launched within the past 5 years; the performance and distribution rate information presented for this Fund reflects data from inception to 10/31/2024.

Shareholders should not draw any conclusions about a Fund’s investment performance from the amount of the Fund’s current distributions or from the terms of the Fund’s Plan.

BlackRock Enhanced Government Fund, Inc. (NYSE: EGF), BlackRock Debt Strategies Fund, Inc. (NYSE: DSU), BlackRock Floating Rate Income Strategies Fund, Inc. (NYSE: FRA), BlackRock Floating Rate Income Trust (NYSE: BGT), BlackRock Corporate High Yield Fund, Inc. (NYSE: HYT), BlackRock Credit Allocation Income Trust (NYSE: BTZ), BlackRock Limited Duration Income Trust (NYSE: BLW), BlackRock Core Bond Trust (NYSE: BHK), BlackRock Multi-Sector Income Trust (NYSE: BIT), BlackRock Income Trust, Inc. (NYSE: BKT) and BlackRock Taxable Municipal Bond Trust (NYSE: BBN) have adopted a Plan to support a level monthly distribution of income, capital gains and/or return of capital. The fixed amounts distributed per share are subject to change at the discretion of each Fund’s Board of Directors/Trustees. Under its Plan, each Fund will distribute all available net income to its shareholders, consistent with its investment objectives and as required by the Code. If sufficient income (inclusive of net investment income and short-term capital gains) is not available on a monthly basis, a Fund will distribute long-term capital gains and/or return capital to its stockholders in order to maintain a level distribution. Each of the above-listed Funds is currently not relying on any exemptive relief from Section 19(b) of the Investment Company Act of 1940, as amended (the “1940 Act”). Each Fund expects that distributions under the Plan will exceed current income and capital gains and therefore will likely include a return of capital. Each Fund may make additional distributions from time to time, including additional capital gain distributions at the end of the taxable year, if required to meet requirements imposed by the Code and/or the 1940 Act.

Each Fund’s estimated sources of the distributions paid as of November 29, 2024 and for its current fiscal year are as follows:

Estimated Allocations as of November 29, 2024

Fund

Distribution

Net Income

Net Realized Short-Term Gains

Net Realized Long-Term Gains

Return of Capital

EGF2

$0.041000

$0.030660 (75%)

$0 (0%)

$0 (0%)

$0.010340 (25%)

BKT2

$0.088200

$0.040551 (46%)

$0 (0%)

$0 (0%)

$0.047649 (54%)

DSU2

$0.098730

$0.077696 (79%)

$0 (0%)

$0 (0%)

$0.021034 (21%)

FRA2

$0.123840

$0.096014 (78%)

$0 (0%)

$0 (0%)

$0.027826 (22%)

BBN2

$0.092900

$0.084923 (91%)

$0 (0%)

$0 (0%)

$0.007977 (9%)

BGT2

$0.120280

$0.091087 (76%)

$0 (0%)

$0 (0%)

$0.029193 (24%)

HYT2

$0.077900

$0.065724 (84%)

$0 (0%)

$0 (0%)

$0.012176 (16%)

BTZ2

$0.083900

$0.060993 (73%)

$0 (0%)

$0 (0%)

$0.022907 (27%)

BLW2

$0.113200

$0.099226 (88%)

$0 (0%)

$0 (0%)

$0.013974 (12%)

BHK2

$0.074600

$0.048859 (65%)

$0 (0%)

$0 (0%)

$0.025741 (35%)

BIT2

$0.123700

$0.083688 (68%)

$0 (0%)

$0 (0%)

$0.040012 (32%)

Estimated Allocations for the Fiscal Year through November 29, 2024

Fund

Distribution

Net Income

Net Realized Short-Term Gains

Net Realized Long-Term Gains

Return of Capital

EGF2

$0.451000

$0.331478 (73%)

$0 (0%)

$0 (0%)

$0.119522 (27%)

BKT2

$0.970200

$0.375393 (39%)

$0 (0%)

$0 (0%)

$0.594807 (61%)

DSU2

$1.086030

$0.814092 (75%)

$0 (0%)

$0 (0%)

$0.271938 (25%)

FRA2

$1.362240

$1.085287 (80%)

$0 (0%)

$0 (0%)

$0.276953 (20%)

BBN2

$1.021900

$0.834551 (82%)

$0 (0%)

$0 (0%)

$0.187349 (18%)

BGT2

$1.323080

$0.982460 (74%)

$0 (0%)

$0 (0%)

$0.340620 (26%)

HYT2

$0.856900

$0.660644 (77%)

$0 (0%)

$0 (0%)

$0.196256 (23%)

BTZ2

$0.922900

$0.620538 (67%)

$0 (0%)

$0 (0%)

$0.302362 (33%)

BLW2

$1.213400

$1.026867 (85%)

$0 (0%)

$0 (0%)

$0.186533 (15%)

BHK2

$0.820600

$0.519873 (63%)

$0 (0%)

$0 (0%)

$0.300727 (37%)

BIT2

$1.360700

$0.846067 (62%)

$0 (0%)

$0 (0%)

$0.514633 (38%)

2The Fund estimates that it has distributed more than its income and net-realized capital gains in the current fiscal year; therefore, a portion of your distribution may be a return of capital. A return of capital may occur, for example, when some or all of the shareholder’s investment is paid back to the shareholder. A return of capital distribution does not necessarily reflect the Fund’s investment performance and should not be confused with ‘yield’ or ‘income’. When distributions exceed total return performance, the difference will reduce the Fund’s net asset value per share.

The amounts and sources of distributions reported are only estimates and are being provided to you pursuant to regulatory requirements and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon each Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. Each Fund will send its stockholders a Form 1099-DIV for the calendar year that will illustrate how to report these distributions for federal income tax purposes.

Fund Performance and Distribution Rate Information:

Fund

Average annual total return (in relation to NAV) for the 5-year period ending on 10/31/2024

Annualized current distribution rate expressed as a percentage of NAV as of 10/31/2024

Cumulative total return (in relation to NAV) for the fiscal year through 10/31/2024

Cumulative fiscal year distributions as a percentage of NAV as 10/31/2024

EGF

(1.59%)

4.90%

1.39%

4.08%

BKT

(1.52%)

8.78%

1.76%

7.32%

DSU

6.42%

11.08%

7.55%

9.24%

FRA

6.63%

11.46%

7.56%

9.55%

BBN

(0.57%)

6.35%

2.66%

5.29%

BGT

6.71%

11.42%

7.65%

9.52%

HYT

5.53%

9.61%

8.34%

8.01%

BTZ

2.98%

8.81%

6.47%

7.34%

BLW

4.81%

9.62%

8.22%

7.79%

BHK

(0.49%)

8.45%

2.97%

7.04%

BIT

5.58%

10.16%

7.65%

8.47%

No conclusions should be drawn about a Fund’s investment performance from the amount of the Fund’s distributions or from the terms of the Fund’s Plan.

The amount distributed per share under a Plan is subject to change at the discretion of the applicable Fund’s Board. Each Plan will be subject to ongoing review by the Board to determine whether the Plan should be continued, modified or terminated. The Board may amend the terms of a Plan or suspend or terminate a Plan at any time without prior notice to the Fund’s shareholders if it deems such actions to be in the best interest of the Fund or its shareholders. The amendment or termination of a Plan could have an adverse effect on the market price of the Fund’s shares.

About BlackRock

BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit www.blackrock.com/corporate

Availability of Fund Updates

BlackRock will update performance and certain other data for the Funds on a monthly basis on its website in the “Closed-end Funds” section of www.blackrock.com as well as certain other material information as necessary from time to time. Investors and others are advised to check the website for updated performance information and the release of other material information about the Funds. This reference to BlackRock’s website is intended to allow investors public access to information regarding the Funds and does not, and is not intended to, incorporate BlackRock’s website in this release.

Forward-Looking Statements

This press release, and other statements that BlackRock or a Fund may make, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act, with respect to a Fund’s or BlackRock’s future financial or business performance, strategies or expectations. Forward-looking statements are typically identified by words or phrases such as “trend,” “potential,” “opportunity,” “pipeline,” “believe,” “comfortable,” “expect,” “anticipate,” “current,” “intention,” “estimate,” “position,” “assume,” “outlook,” “continue,” “remain,” “maintain,” “sustain,” “seek,” “achieve,” and similar expressions, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may” or similar expressions.

BlackRock cautions that forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and BlackRock assumes no duty to and does not undertake to update forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements and future results could differ materially from historical performance.

With respect to the Funds, the following factors, among others, could cause actual events to differ materially from forward-looking statements or historical performance: (1) changes and volatility in political, economic or industry conditions, the interest rate environment, foreign exchange rates or financial and capital markets, which could result in changes in demand for the Funds or in a Fund’s net asset value; (2) the relative and absolute investment performance of a Fund and its investments; (3) the impact of increased competition; (4) the unfavorable resolution of any legal proceedings; (5) the extent and timing of any distributions or share repurchases; (6) the impact, extent and timing of technological changes; (7) the impact of legislative and regulatory actions and reforms, and regulatory, supervisory or enforcement actions of government agencies relating to a Fund or BlackRock, as applicable; (8) terrorist activities, international hostilities, health epidemics and/or pandemics and natural disasters, which may adversely affect the general economy, domestic and local financial and capital markets, specific industries or BlackRock; (9) BlackRock’s ability to attract and retain highly talented professionals; (10) the impact of BlackRock electing to provide support to its products from time to time; and (11) the impact of problems at other financial institutions or the failure or negative performance of products at other financial institutions.

Annual and Semi-Annual Reports and other regulatory filings of the Funds with the Securities and Exchange Commission (“SEC”) are accessible on the SEC’s website at www.sec.govand on BlackRock’s website at www.blackrock.com, and may discuss these or other factors that affect the Funds. The information contained on BlackRock’s website is not a part of this press release.

1-800-882-0052

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Asset Management Professional Services Finance

MEDIA:

Logo
Logo
Posted on

BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity

Decision follows observations of liver transaminitis without clinically significant symptoms in some subjects on azelaprag

Company will evaluate data from patients enrolled to date and share updated plans for azelaprag in Q1 2025

In parallel to evaluating azelaprag, Company will continue to advance earlier platform-derived programs, including IND submission for CNS penetrant NLRP3 inhibitor anticipated in the second half of 2025

RICHMOND, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) — BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company has made the decision to discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate azelaprag as monotherapy and in combination with tirzepatide after liver transaminitis without clinically significant symptoms was observed in some subjects receiving azelaprag. No transaminase elevations were observed in the tirzepatide only treatment group.

“Patient safety is our top priority in the conduct of our clinical studies,” said Kristen Fortney, PhD, CEO and co-founder of BioAge. “We made the difficult decision to discontinue the STRIDES Phase 2 study of azelaprag because it became clear that the emerging safety profile of the current doses tested is not consistent with our goal of a best-in-class oral obesity therapy. While this outcome is a significant disappointment, we remain encouraged by azelaprag’s promising preclinical and Ph1b efficacy profile. We remain committed to our focus on developing therapies for metabolic aging. In parallel to assessing the next steps for the azelaprag program, we will continue to advance our NLRP3 inhibitor program as well as additional research programs with novel mechanisms emerging from our platform.”

STRIDES is a randomized, double-blind, placebo-controlled Phase 2 clinical trial of azelaprag as monotherapy and in combination with tirzepatide that planned to enroll approximately 220 individuals with obesity aged 55 years and older (link). The trial was designed to evaluate the efficacy as measured by body weight reduction and other outcomes, safety, and tolerability of two oral doses of azelaprag (300 mg, once or twice daily) in combination with tirzepatide (5 mg subcutaneous injection once weekly). An azelaprag monotherapy arm was included to provide additional safety information.

Of 204 subjects enrolled in STRIDES as of today, 11 subjects in the azelaprag treatment groups were observed to have transaminase elevations with no clinically significant symptoms. Dosing of all subjects will be discontinued, and no additional subjects will be enrolled. Clinical follow-up of enrolled subjects will continue off drug. The Company intends to further analyze available STRIDES clinical data from all enrolled subjects. The Company has notified all study investigators and regulatory authorities including the U.S. Food and Drug Administration (FDA) of the Company’s decision to discontinue enrollment.   The Company intends to share updated plans for azelaprag in Q1 2025.

BioAge continues to advance its pipeline of therapeutic candidates targeting the biology of aging to treat metabolic diseases. The Company’s novel class of brain-penetrant NLRP3 inhibitors, which have demonstrated high potency and a novel binding site, are progressing toward IND submission, anticipated in the second half of 2025. The NLRP3 inhibitor program targets neuroinflammation, which is linked to both metabolic and neurodegenerative diseases. In addition, BioAge is advancing multiple targets derived from its proprietary discovery platform, which analyzes molecular data spanning over 50 years of human aging trajectories.

About BioAge Labs, Inc.

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. BioAge’s lead product candidate, azelaprag, is an orally available small molecule agonist of APJ that was observed to promote metabolism and prevent muscle atrophy on bed rest in a Phase 1b clinical trial. BioAge is also developing orally available small molecule brain penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. BioAge’s preclinical programs, based on novel insights from the company’s discovery platform built on human longevity data, address key pathways in metabolic aging.

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our plans to develop and commercialize our product candidates, our business strategy, results of our ongoing or planned clinical trials, the timing of any future updates to our programs and the clinical utility of our product candidates. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “potential,” “possible,” “will,” “would,” and other words and terms of similar meaning. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our ability to develop, obtain regulatory approval for and commercialize our product candidates; the timing and results of preclinical studies and clinical trials; the risk that positive results in a preclinical study or clinical trial may not be replicated in subsequent trials or success in early stage clinical trials may not be predictive of results in later stage clinical trials; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events; failure to protect and enforce our intellectual property, and other proprietary rights; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; risks relating to technology failures or breaches; our dependence on collaborators and other third parties for the development of product candidates and other aspects of our business, which are outside of our full control; risks associated with current and potential delays, work stoppages, or supply chain disruptions; risks associated with current and potential future healthcare reforms; risks relating to attracting and retaining key personnel; failure to comply with legal and regulatory requirements; risks relating to access to capital and credit markets; and the other risks and uncertainties that are detailed under the heading “Risk Factors” included in BioAge’s Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) on November 7, 2024, and other filings with the SEC filed from time to time. BioAge undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contacts

PR: Chris Patil, [email protected]
IR: Elena Liapounova, [email protected]
Partnering: [email protected]
Web: https://bioagelabs.com



Posted on

DWS Municipal Income Trust Declares Monthly Distribution

DWS Municipal Income Trust Declares Monthly Distribution

NEW YORK–(BUSINESS WIRE)–DWS Municipal Income Trust (KTF) (the “Fund”) announced today its regular November monthly distribution.

Details are as follows:

Declaration – 12/06/2024        Ex-Date – 12/18/2024        Record – 12/18/2024        Payable – 12/30/2024

Fund

Ticker

Distribution

Per Share

Prior

Distribution

Per Share

 

DWS Municipal Income Trust

 

KTF

 

$0.0610

 

$0.0610

The Fund intends to distribute all or substantially all of its net investment income each year through its regular monthly distributions and to distribute any realized capital gains at least annually. In addition, in any monthly period, to maintain its declared per common share distribution amount, the Fund may distribute more or less than its net investment income during the period. In the event the Fund distributes more than its net investment income during any yearly period, such distributions may also include realized gains and/or a return of capital. When distributions exceed total return performance, the difference will reduce the Fund’s net asset value.

It is estimated that a portion of the Fund’s December distribution consists of a return of capital. A return of capital may occur, for example, when some or all of a shareholder’s investment is paid back to the shareholder. A return of capital distribution does not necessarily reflect a fund’s investment performance and should not be confused with “yield” or “income.” Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of its monthly distribution. As required by Federal securities laws, the Fund will issue a notice to its common shareholders in connection with its monthly distribution that contains information about the amount and estimated sources of the distribution and other related information. The final determination of the source and tax status of all distributions paid in 2024 will be made after the end of 2024 and will be provided on Form 1099-DIV.

Important Information

DWS Municipal Income Trust. Bond investments are subject to interest-rate, credit, liquidity and market risks to varying degrees. When interest rates rise, bond prices generally fall. Credit risk refers to the ability of an issuer to make timely payments of principal and interest. Municipal securities are subject to the risk that litigation, legislation or other political events, local business or economic conditions or the bankruptcy of the issuer could have a significant effect on an issuer’s ability to make payments of principal and/or interest. The market for municipal bonds may be less liquid than for taxable bonds, and there may be less information available on the financial condition of issuers of municipal securities than for public corporations. Investing in derivatives entails special risks relating to liquidity, leverage and credit that may reduce returns and/or increase volatility. Leverage results in additional risks and can magnify the effect of any gains or losses. Although the Fund seeks income that is exempt from federal income taxes, a portion of the Fund’s distributions may be subject to federal, state and local taxes, including the alternative minimum tax.

Closed-end funds, unlike open-end funds, are not continuously offered. There is a one-time public offering and once issued, shares of closed-end funds are bought and sold in the open market through a stock exchange. Shares of closed-end funds frequently trade at a discount to the net asset value. The price of a fund’s shares is determined by a number of factors, several of which are beyond the control of the fund. Therefore, the fund cannot predict whether its shares will trade at, below or above net asset value.

Past performance is no guarantee of future results.

This press release shall not constitute an offer to sell or a solicitation to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer or solicitation or sale would be unlawful prior to registration or qualification under the laws of such state or jurisdiction.

Certain statements contained in this release may be forward-looking in nature. These include all statements relating to plans, expectations, and other statements that are not historical facts and typically use words like “expect,” “anticipate,” “believe,” “intend,” ”estimated” and similar expressions. Such statements represent management’s current beliefs, based upon information available at the time the statements are made, with regard to the matters addressed. All forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in, or implied by, such statements. Management does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. The following factors, among others, could cause actual results to differ materially from forward-looking statements: (i) the effects of adverse changes in market and economic conditions; (ii) legal and regulatory developments; and (iii) other additional risks and uncertainties, including public health crises (including the pandemic spread of viruses), war, terrorism, trade disputes and related geopolitical events.

War, terrorism, sanctions, economic uncertainty, trade disputes, public health crises and related geopolitical events have led, and, in the future, may lead to significant disruptions in US and world economies and markets, which may lead to increased market volatility and may have significant adverse effects on the Fund and its investments.

NOT FDIC/ NCUA INSURED • MAY LOSE VALUE • NO BANK GUARANTEE

NOT A DEPOSIT • NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCY

DWS Distributors, Inc.

222 South Riverside Plaza

Chicago, IL 60606-5808

www.dws.com

Tel (800) 621-1148

© 2024 DWS Group GmbH & Co. KGaA. All rights reserved.

The brand DWS represents DWS Group GmbH & Co. KGaA and any of its subsidiaries such as DWS Distributors, Inc. which offers investment products or DWS Investment Management Americas, Inc. and RREEF America L.L.C. which offer advisory services. (R-103920 -1) (12/24)

For additional information:

DWS Press Office (212) 454-4500

Shareholder Account Information (800) 294-4366

DWS Closed-End Funds (800) 349-4281

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Asset Management Professional Services Finance

MEDIA:

Logo
Logo
Posted on

Cerence AI Announces Equity Grant to Employee Under Inducement Plan Pursuant to Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC) (“Cerence AI”), a global industry leader in AI for transportation, today announced that, in connection with Antonio (“Tony”) Rodriquez’s recent appointment as Executive Vice President, Chief Financial Officer effective November 29, 2024, the Company granted Mr. Rodriquez 313,283 time-based restricted stock units and 313,283 performance-based restricted stock units. The time-based restricted stock units will vest in three equal installments on each of October 1, 2025, October 1, 2026, and October 1, 2027, in each case subject to Mr. Rodriquez’s continued service with the Company through the applicable vesting date. The performance-based restricted stock units will be earned based on the achievement of the Company’s performance metrics for each of fiscal year 2025, 2026 and 2027 with one-third of the total performance-based restricted stock units eligible to be earned for each fiscal year, subject to Mr. Rodriquez’s continued service with the Company through such vesting date. All of these awards were granted as an inducement material to Mr. Rodriquez entering into employment with the Company pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

To learn more about Cerence AI, visit www.cerence.ai, and follow the company on LinkedIn.

About Cerence Inc.

Cerence Inc. (NASDAQ: CRNC) is a global industry leader in creating intuitive, seamless, AI-powered experiences across automotive and transportation. Leveraging decades of innovation and expertise in voice, generative AI, and large language models, Cerence powers integrated experiences that create safer, more connected, and more enjoyable journeys for drivers and passengers alike. With more than 500 million cars shipped with Cerence technology, the company partners with leading automakers, transportation OEMs, and technology companies to advance the next generation of user experiences. Cerence is headquartered in Burlington, Massachusetts, with operations globally and a worldwide team dedicated to pushing the boundaries of AI innovation. For more information, visit www.cerence.ai.

Contact Information

Kate Hickman | Tel: 339-215-4583 | Email: [email protected]



Posted on

HII’s Ingalls Shipbuilding Undocks USS Zumwalt (DDG 1000)

PASCAGOULA, Miss., Dec. 06, 2024 (GLOBE NEWSWIRE) — HII’s (NYSE: HII) Ingalls Shipbuilding division successfully undocked USS Zumwalt (DDG 1000), the lead ship of the U.S. Navy’s Zumwalt-class of guided missile destroyers, taking the ship one step closer to testing and returning to the U.S. Navy fleet.  

“In partnership with the Navy we are steadfast in our commitment to complete this complex work that adds significant hypersonic capability to Zumwalt,” HII President and CEO Chris Kastner said. “We are proud to support the incorporation of the conventional prompt strike for the Navy.”

The undocking marked the completion of significant modernization work at Ingalls since the ship arrived at the Pascagoula shipyard in August 2023. Shortly after its arrival, the ship was put back on land in order to receive technology upgrades including the integration of the Conventional Prompt Strike (CPS) weapon system. The Ingalls team also replaced the original twin 155mm Advanced Gun Systems on the destroyers with new missile tubes.

Zumwalt-class destroyers feature a state-of-the-art electric propulsion system, wave-piercing tumblehome hull, stealth design and is equipped with the most advanced warfighting technology and weaponry. These ships will be capable of performing a range of deterrence, power projection, sea control, and command and control missions while allowing Navy to evolve with new systems and missions.

Photos accompanying this release are available at: https://hii.com/news/hiis-ingalls-shipbuilding-undocks-uss-zumwalt-ddg-1000/.

About HII

HII is a global, all-domain defense provider. HII’s mission is to deliver the world’s most powerful ships and all-domain solutions in service of the nation, creating the advantage for our customers to protect peace and freedom around the world.

As the nation’s largest military shipbuilder, and with a more than 135-year history of advancing U.S. national security, HII delivers critical capabilities extending from ships to unmanned systems, cyber, ISR, AI/ML and synthetic training. Headquartered in Virginia, HII’s workforce is 44,000 strong. For more information, visit:

Contact:

Kimberly K. Aguillard
228-355-5663
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/eb1ca1f1-d87c-42d3-9375-1a3008cdf656



Posted on

M3 Group Joins MEDIROM Mother Labs’ Series A Financing Round at JPY9 Billion (as of December 1, 2024, approximately USD $59,000,000) Pre-Money Valuation

TOKYO, Dec. 06, 2024 (GLOBE NEWSWIRE) — MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) announces that M3, Inc. (TOKYO PRIME: 2413), or an affiliate within the M3 group, is participating in the Series A equity financing round of MEDIROM MOTHER Labs Inc., a subsidiary of MEDIROM. NFES Technologies Inc. is the lead investor of the Series A financing round at a pre-money valuation of JPY9 billion. Additional information is available here: https://medirom.co.jp/en/ir/20240824/6148%09

Forward-Looking Statements Regarding MEDIROM

Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about MEDIROM’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal,” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to MEDIROM’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause MEDIROM’s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond MEDIROM’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects MEDIROM’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to MEDIROM’s operations, results of operations, growth strategy and liquidity.

More information on these risks and other potential factors that could affect MEDIROM’s business, reputation, results of operations, financial condition, and stock price is included in MEDIROM’s filings with the Securities and Exchange Commission (the “SEC”), including in the “Risk Factors” and “Operating and Financial Review and Prospects” sections of MEDIROM’s most recently filed periodic report on Form 20-F and subsequent filings, which are available on the SEC website at www.sec.gov. MEDIROM assumes no obligation to update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ from those anticipated in these forward-looking statements, even if new information becomes available in the future.

ABOUT M3, Inc.

M3 is a one of a kind venture company that operates a multitude of global services centred around its physician platform such as m3.com.

M3 is the first company incorporated after the year 2000 to be included in the Nikkei 225 Index. Its 330,000+ Japanese and 6,500,000+ global physician member panel serves as a central platform in advancing innovation and reform across healthcare worldwide.

Tokyo Stock Exchange Prime Market (Securities code 2413)
1-11-44 Akasaka Minato-ku, Tokyo 107-0052 JAPAN
Web https://corporate.m3.com/en

ABOUT MEDIROM MOTHER Labs Inc.

A subsidiary of MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), focuses on the health-tech sector. The company’s core activities include the “Specific Health Guidance Program” offered through the “Lav” health application and development and sales of the 24/7 recharge-free MOTHER Bracelet smart tracker. By leveraging the features of the recharge-free MOTHER Bracelet, MOTHER Labs offers customizable health management solutions across diverse sectors, including caregiving, logistics, manufacturing, etc.

MEDIROM Healthcare Technologies Inc.

NASDAQ Symbol: MRM
Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan
Web https://medirom.co.jp/en
Contact: [email protected]

MEDIROM MOTHER Labs Inc.

Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan

MOTHER Bracelet is the world’s first* 24/7 recharge-free smart tracker. It uses innovative technology from a Silicon Valley tech company that allows for power generation based on temperature differences between body and surrounding air. The recharge-free feature eliminates the risk of data loss when a device is taken off for recharge. MOTHER Bracelet records five basic metrics: heart rate, calories burned, body surface temperature, step count, and sleep.
Official Website: https://mother-bracelet.com



Posted on

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 9,450 shares of its common stock under the Company’s 2023 Inducement Plan.

The stock options will vest over a four-year period, with 25% of each of the options vesting on the first anniversary of such employee’s start date, and 1/48th of the total shares vesting monthly thereafter, subject to continued employment on each vesting date.

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com.

Investor & Media Contacts:

Sylvia Wheeler
Wheelhouse Life Science Advisors
[email protected]

Aljanae Reynolds
Wheelhouse Life Science Advisors
[email protected]

1 If approved by the FDA



Posted on

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del.–(BUSINESS WIRE)–
Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 7,259 shares of the Company’s common stock to 15 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of December 2, 2024, and were approved by the compensation committee of the Company’s board of directors as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Each RSU vests as to 25% of the shares subject to the RSU on each of the first four anniversaries of the vesting commencement date, subject to the employee’s continued service with the Company on each such date.

About Incyte

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.

Media

[email protected]

Investors

[email protected]

KEYWORDS: United States North America Delaware

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Oncology

MEDIA:

Logo
Logo
Posted on

Blackstone Completes Senior Notes Offering

Blackstone Completes Senior Notes Offering

NEW YORK–(BUSINESS WIRE)–
Blackstone (NYSE: BX) announced the completion of the previously announced offering of $750 million of 5.000% senior notes due 2034 of Blackstone Reg Finance Co. L.L.C., its indirect subsidiary. The notes are fully and unconditionally guaranteed by Blackstone Inc. and its indirect subsidiaries, Blackstone Holdings I L.P., Blackstone Holdings AI L.P., Blackstone Holdings II L.P., Blackstone Holdings III L.P. and Blackstone Holdings IV L.P. Blackstone intends to use the proceeds from the notes offering for general corporate purposes.

The notes were offered pursuant to an effective shelf registration statement on file with the U.S. Securities and Exchange Commission (the “SEC”) and only by means of a prospectus and related prospectus supplement. An electronic copy of the prospectus supplement, together with the accompanying prospectus, is available on the SEC’s website at www.sec.gov. Alternatively, copies of the prospectus supplement and accompanying prospectus may be obtained from: BofA Securities, Inc., telephone: 1-800-294-1322; Citigroup Global Markets Inc., telephone: 1-800-831-9146; Morgan Stanley & Co. LLC, telephone: 1-866-718-1649; RBC Capital Markets, LLC, telephone: 1-866-375-6829; or SMBC Nikko Securities America, Inc., telephone: 1-212-224-5135.

This press release shall not constitute an offer to sell or a solicitation of an offer to purchase the notes or any other securities, and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.

Investor and Media Relations Contacts

For Investors

Weston Tucker

Blackstone

Tel: +1 (212) 583-5231

[email protected]

For Media

Matthew Anderson

Blackstone

Tel: +1 (212) 390-2472

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Asset Management Professional Services Finance

MEDIA:

Logo
Logo